-
Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024.
-
Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023.
-
General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million for the year ended December 31, 2023.
Release Date: April 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
AIM ImmunoTech Inc (AIM) announced a new clinical study evaluating Ampligen in combination with AstraZeneca’s FluMist as a potential intranasal vaccine for influenza, including avian flu.
-
The company strengthened its leadership team by adding two experienced Board members, Ted Kellner and David Chemerow, to guide strategic execution.
-
The Erasmus Medical Center Safety Committee approved the continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial, marking progress in their clinical programs.
-
AIM ImmunoTech Inc (AIM) reported final clinical results from the AMP-518 study, reinforcing Ampligen’s potential in treating post-COVID conditions.
-
The company expanded its intellectual property estate with new patents in the US and Netherlands, enhancing protection for Ampligen’s applications.
-
AIM ImmunoTech Inc (AIM) reported a decrease in cash, cash equivalents, and marketable securities to approximately $4 million as of December 31, 2024.
-
Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating potential budget constraints.
-
General and administrative expenses also decreased from $21.1 million in 2023 to $13.7 million in 2024, which may reflect cost-cutting measures.
-
The company is facing challenges in maintaining its listing on the New York Stock Exchange American and is considering a reverse stock split to avoid delisting.
-
Future clinical trials will require additional manufacturing of Ampligen, which necessitates capital investment and could pose a financial challenge.
Q: Do you have adequate supply of Ampligen for all your clinical trials this year, and how easy would it be to get new supply? A: Thomas Equels, President, CEO, and Executive Vice Chairman, responded that they have a budget for Ampligen tied to ongoing clinical activities, ensuring sufficient supply for current trials. For future trials, manufacturing more Ampligen will require capital, but they are actively working with polymer manufacturers and other vendors to ensure a steady supply. They do not anticipate any supply issues unless unforeseen circumstances arise.
